Esperion Therapeutics (ESPR) Tops Q3 EPS by 18c; Reports Cash and Cash Equivalents of $153.7M

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($2.62), $0.18 better than the analyst estimate of ($2.80). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $12.85 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Ecolab closes CoolIT acquisition for $4.75 billion
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy